Neurologic manifestations in hospitalized patients with COVID-19
- 1 June 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 95 (8), e1060-e1070
- https://doi.org/10.1212/wnl.0000000000009937
Abstract
Objective The coronavirus disease 2019 (COVID-19) has spread worldwide since December 2019. Neurologic symptoms have been reported as part of the clinical spectrum of the disease. We aimed to determine whether neurologic manifestations are common in hospitalized patients with COVID-19 and to describe their main characteristics. Methods We systematically reviewed all patients diagnosed with COVID-19 admitted to the hospital in a Spanish population during March 2020. Demographic characteristics, systemic and neurologic clinical manifestations, and complementary tests were analyzed. Results Of 841 patients hospitalized with COVID-19 (mean age 66.4 years, 56.2% men), 57.4% developed some form of neurologic symptom. Nonspecific symptoms such as myalgias (17.2%), headache (14.1%), and dizziness (6.1%) were present mostly in the early stages of infection. Anosmia (4.9%) and dysgeusia (6.2%) tended to occur early (60% as the first clinical manifestation) and were more frequent in less severe cases. Disorders of consciousness occurred commonly (19.6%), mostly in older patients and in severe and advanced COVID-19 stages. Myopathy (3.1%), dysautonomia (2.5%), cerebrovascular diseases (1.7%), seizures (0.7%), movement disorders (0.7%), encephalitis (n = 1), Guillain-Barré syndrome (n = 1), and optic neuritis (n = 1) were also reported, but less frequent. Neurologic complications were the main cause of death in 4.1% of all deceased study participants. Conclusions Neurologic manifestations are common in hospitalized patients with COVID-19. In our series, more than half of patients presented some form of neurologic symptom. Clinicians need to maintain close neurologic surveillance for prompt recognition of these complications. The mechanisms and consequences of severe acute respiratory syndrome coronavirus type 2 neurologic involvement require further studies.This publication has 28 references indexed in Scilit:
- Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic MechanismsACS Chemical Neuroscience, 2020
- Th17 lymphocytes drive vascular and neuronal deficits in a mouse model of postinfectious autoimmune encephalitisProceedings of the National Academy of Sciences, 2020
- The neuroinvasive potential of SARS‐CoV2 may play a role in the respiratory failure of COVID‐19 patientsJournal of Medical Virology, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Coronavirus infections and immune responsesJournal of Medical Virology, 2020
- Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disordersMultiple Sclerosis and Related Disorders, 2019
- Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapyBone Marrow Transplantation, 2019
- Obesity and type 2 diabetes mellitus drive immune dysfunction, infection development, and sepsis mortalityJournal of Leukocyte Biology, 2018
- Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in AdultsClinical Infectious Diseases, 2007
- Myopathic Changes Associated With Severe Acute Respiratory SyndromeArchives of Neurology, 2005